---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009483"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:27:32.182974+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma reports FY2022 net loss of $95.6M ($2.53/sh); cash $245.2M; $10M legal settlement

## Summary
- Net loss $95.6M ($2.53 EPS) vs $54.9M ($1.49 EPS) in 2021; R&D spend rose 44% to $61.5M.
- Cash, equivalents and investments $245.2M at Dec 31, 2022, vs $319.7M year earlier.
- Recorded $10M legal settlement expense for securities class action; subject to court approval.
- Targeting LIFT-AD Phase 2/3 enrollment completion mid-2023, topline data early 2024.
- ATH-1105 (ALS) IND-enabling studies ongoing; Phase 1 expected in 2024.

## SEC filing metadata
- accession: 0000950170-23-009483
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/0000950170-23-009483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/atha-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009483
- JSON: https://secwatch.observer/filing/0000950170-23-009483.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009483.txt

## Key facts
- Earnings Releases
  LeonaBio, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009483/0000950170-23-009483-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.